X Bioscience Public Company Limited

X Bioscience Public Company Limited

0.05
THB
0.00
(0.00%)
-0.09EPS
851.46MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
82.43
85.59
61.64
53.25
55.33
37.95
14.13
0.99
0.51
0.68
0.58
0.13
0.17
0.03
Basic EPS, GAAP
-5.86
-105.03
-69.14
-39.14
-31.66
0.67
-0.73
-0.57
-0.55
-1.14
-0.27
-0.11
-0.62
-0.09
Free Cash Flow per Basic Share
5.92
-12.61
-6.88
-12.54
-3.59
-1.55
-3.26
-0.16
-0.42
-0.58
-0.25
-0.02
-0.1
-0.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
256.89
191.72
123.66
88.93
58.02
58.57
27.96
1.88
1.34
0.2
0.29
0.43
0.11
0.02
Tangible Book Value per Share
255.61
191.47
123.44
88.75
53.74
54.3
8.1
0.04
-0.41
-0.63
-0.33
-0.12
0.01
0.02
Basic Weighted Avg Shares
2
2
3
3
4
8
30
420
503
503
542
2,421
755
7,549
Sales/Revenue/Turnover
187
181
174
183
230
298
425
416
254
344
312
319
130
209
Operating Margin (%)
-14.34
-57.9
-78.92
-79.03
-7.18
5.16
-19.34
-31.67
-39.58
-82.22
-38.63
-78.69
-350.4
-262.1
Depreciation Expense
15
12
10
28
21
43
65
92
120
146
47
67
40
33
Net Income, GAAP
-13
-222
-196
-135
-132
5
-22
-239
-276
-574
-148
-260
-469
-655
Effective Tax Rate (%)
- -
- -
- -
- -
- -
63.27
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7.11
-122.71
-112.17
-73.51
-57.22
1.76
-5.15
-57.46
-108.82
-166.64
-47.32
-81.51
-361.63
-312.51
Working Capital
380
343
333
250
293
301
277
-70
-358
-402
-355
-326
-24
82
LT Debt
- -
- -
29
30
30
93
83
110
128
102
92
77
40
3
Total Equity
583
519
415
313
552
557
964
948
673
103
183
827
223
358
Return on Invested Capital (%)
- -
- -
- -
- -
- -
0.89
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
1.17
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-2.26
-40.31
-41.9
-37.02
-30.41
0.94
-3.25
-27.51
-34.1
-147.96
-103.4
-74.74
-128.43
-184.67

Capital Structure

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
201
141
126
LT Borrowings
4
3
- -
LT Finance Leases
36
34
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,973
12,151
12,164
Market Capitalization
179
851
851

Working Capital

THB

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
302
310
355
Cash, Cash Equivalents & STI
2
27
5
Accounts Receivable, Net
- -
52
55
Inventories
2
2
7
Total Current Liabilities
326
318
273
Payables & Accruals
125
170
77
ST Debt
201
141
126
Deferred Revenue
- -
8
1

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
36.83%
48.83%
-73.03%
Free Cash Flow
89.42%
36.46%
43.84%
Net Income, GAAP
54.12%
41.14%
80.18%
Sales/Revenue/Turnover
3.08%
-13.95%
-59.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
76
72
73
99
319
2025
53
20
26
24
130
2026
83
77
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.07
-0.09
-0.13
-0.12
-0.11
2025
-0.05
-0.05
-0.1
-0.09
-0.62
2026
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Amnart Lertpresertwong
Full Time Employees
399
Sector
Consumer services
Industry
Restaurants
Address
No. 304, Vanit Place Building A Bangkok BM Thailand 10400
IPO Date
Dec 22, 2003
Website
xbio.co.th
Business
X Bioscience Public Company Limited (XBIO) engages in the sale of food and beverages in Thailand and operates related restaurant, energy, and manufacturing activities. The company manufactures and sells biological products and leverages its culinary brands to drive consumer and institutional channels. XBIO, founded in 1984, is headquartered in Bangkok, Thailand, and maintains a diversified portfolio across dining concepts, brand franchises, and ancillary business lines. Main Products and Services: food and beverage distribution and retail activities under brands such as Kagonoya, Le Boeuf, and Bake Cheese Tart; restaurant operations across owned and franchised formats; manufacturing and sale of biological products; energy generation and transmission activities; ancillary services related to supply chain management, distribution, and brand licensing; and investment in related hospitality and consumer-services ventures. Latest Major Company Changes: undergoes corporate rebranding and name change from Wow Factor Public Company Limited to X Bioscience Public Company Limited in January 2025; expands strategic footprint through new brand launches and potential partnerships in foodservice and retail platforms; pursues corporate restructurings and roadmap adjustments to align with integrated food, beverage, and bioscience product initiatives; advances in energy-related operations and potential collaborations within Southeast Asia. Additional Context: operates within the consumer staples and hospitality sectors with a focus on branded foodservice concepts, culinary experiences, and bioscience product lines; targets leisure and dining consumers, hotel and retail customers, and institutional buyers; geographic footprint centered in Thailand with potential regional activity in Southeast Asia; corporate structure includes subsidiaries and potential parent-subsidiary relationships aligned with brand portfolios and manufacturing capabilities.